CurrentBlue Cross Blue Shield - MassachusettsPolicy 190

Allogeneic Hematopoietic Stem Cell Transplantation (allo‑HCT)

Medical necessity and prior authorization requirements for allogeneic hematopoietic stem cell transplantation for commercial members of Blue Cross Blue Shield of Massachusetts, including covered indications and coding guidance.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyAllogeneic Hematopoietic Stem Cell Transplantation (allo‑HCT)

Policy CodePolicy 190

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit initial prior authorization requests using Authorization Manager and include the servicing provider's and facility's NPI.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

select disordersindications medically necessary

prior auth requiredinpatient procedures

prior auth requiredoutpatient (commercial)

38240example CPT

S2142, S2150included HCPCS

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Hunter/Sanfilippo/Morquioinsufficient evidence

Coverage Criteria for Allogeneic Hematopoietic Stem Cell Transplantation

Medically Necessary Indications

Allogeneic hematopoietic stem cell transplantation is considered MEDICALLY NECESSARY for select patients when ALL of the indication-specific criteria are met:

Hemoglobinopathies: Includes homozygous beta-thalassemia (thalassemia major) and sickle cell anemia for children or young adults with a history of prior stroke or who are at increased risk of stroke or end-organ damage.

supported by chunks 4 and 19

Bone Marrow Failure Syndromes: Includes aplastic anemia (hereditary or acquired), including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond, and Diamond-Blackfan syndromes.

supported by chunk 5 and 21

Primary Immunodeficiencies: Includes absent or defective NK, T-cell, or neutrophil function and other severe primary immunodeficiencies (eg, severe combined immunodeficiency, Wiskott-Aldrich syndrome) that have been successfully treated with allo-HCT.

supported by chunk 6 and 23

Inherited Metabolic Diseases: Includes selected lysosomal and peroxisomal storage disorders for which allo-HCT has demonstrated effectiveness (exceptions noted below for Hunter, Sanfilippo, and Morquio syndromes).

supported by chunk 10 and 25

Genetic Disorders Affecting Skeletal Tissue: Includes infantile malignant osteopetrosis (severe osteopetrosis) as an indication where allo-HCT is used to restore marrow function.

supported by chunk 11 and 28

Covered Indications

Covered when the following disease-specific considerations apply and transplantation is intended as curative or to substantially alter disease natural history:

Indications: Allo-HCT is used for select patients with hemoglobinopathies (eg, thalassemia major, sickle cell disease), bone marrow failure syndromes (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan, Shwachman-Diamond), severe primary immunodeficiencies (including severe combined immunodeficiency, Wiskott-Aldrich), certain inherited metabolic diseases (many lysosomal and peroxisomal storage disorders, excluding Hunter, Sanfilippo, and Morquio syndromes where neurologic benefit is not demonstrated), and genetic disorders affecting skeletal tissue (eg, infantile malignant osteopetrosis).N/A

Evidence supports improved overall and disease-specific survival for many of these disorders; insufficient evidence of neurologic benefit for Hunter, Sanfilippo, and Morquio syndromes.

Certain inherited metabolic disorders are explicitly treated as exceptions in this policy. The policy lists lysosomal and peroxisomal storage disorders as potential indications but excludes Hunter, Sanfilippo, and Morquio syndromes from that group of disorders for which allo-HCT is considered effective.

For Hunter, Sanfilippo, and Morquio syndromes, the available evidence does not demonstrate neurologic, neuropsychologic, or neurophysiologic improvement following allogeneic hematopoietic stem cell transplantation; therefore, allo-HCT is not supported as providing neurologic benefit for these specific mucopolysaccharide disorders.

No additional exclusions for inherited metabolic disorders are listed in the referenced bibliographic material included in this policy excerpt; exclusions and disorder‑specific guidance are addressed in the main policy text and the exclusion statements shown above.

The policy acknowledges that evidence supporting allo-HCT varies by inherited metabolic disorder. While allo-HCT has proven benefit for named disorders such as Hurler syndrome and certain leukodystrophies, the evidence base for other specific inherited metabolic diseases is limited to case reports and small series, and therefore is considered insufficient to determine net health benefit in some syndromes (notably Hunter, Sanfilippo, and Morquio).

This section is reference‑only and does not add procedural requirements; consult the main policy and the cited literature in the bibliography for disorder‑specific outcome data and long‑term follow‑up studies.

Candidate Selection and Indications

Candidate Criteria

Candidate selection is indication-specific as listed below.

Hemoglobinopathy candidates: Patients with homozygous beta-thalassemia (thalassemia major) or children/young adults with sickle cell disease who have had a prior stroke or are at increased risk of stroke or end-organ damage and for whom allo-HCT is intended as a curative therapy.

chunks 4 and 19

Candidate Conditions

Disease categories and key clinical rationales for considering allo-HCT:

Hemoglobinopathies: Thalassemia major: allo-HCT is the only definitive cure for the genetic defect and avoids lifelong transfusion dependence and progressive iron overload. Sickle cell disease: allo-HCT is the only curative option for selected patients among therapies such as chronic transfusion and hydroxyurea; considered for those with prior stroke or high risk of severe end-organ complications.N/A

Contraindications and Fitness for Transplant

Patients must be medically fit to tolerate the selected conditioning regimen. Intense myeloablative conditioning is associated with substantial toxicity and should be limited to individuals who can tolerate these adverse effects; conditioning intensity should be tailored to patient fitness to minimize treatment‑related morbidity and mortality.

Coding Guidance

Covered CPT CodesCPTCovered

38240

Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic

Covered HCPCS CodesHCPCSCovered

S2142	Cord blood derived stem-cell transplantation, allogeneic
S2150	Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)

HCPCS Codes (Neutral Listing)HCPCS

S2142	Cord blood derived stem-cell transplantation, allogeneic
S2150	Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization Required — inpatient and outpatient settings: Prior authorization (precertification) is required for services described in this policy when performed in the inpatient setting for all products. For outpatient services, prior authorization is required for Commercial Managed Care (HMO and POS), Commercial PPO, and Indemnity products. Inclusion of a code does not guarantee coverage — verify the member's contract benefits in effect at the time of service.

Inpatient services: prior authorization required for all products.
Outpatient services: prior authorization required for Commercial Managed Care (HMO and POS), Commercial PPO, and Indemnity.

Note

Requesting Prior Authorization Using Authorization Manager

Use Authorization Manager to submit initial authorization requests and supporting clinical documentation. Authorization Manager is available 24/7 and is the quickest method to review authorization requirements, request authorizations, submit clinical documentation, check existing case status, and view/print the decision letter. For commercial members, requests must meet medical policy guidelines.

Pretransplant Evaluation and Workup

Prior Authorization

Use Authorization Manager and include NPIs on evaluation submissions

Submit initial authorization requests through Authorization Manager and include the servicing provider's NPI/provider ID and the facility's NPI/provider ID to allow accurate routing and processing.

Documentation Required

HLA typing and fitness assessment required for pretransplant evaluation

Pretransplant evaluation documentation must include HLA typing to establish donor compatibility and assessment of fitness for the conditioning regimen as part of the evaluation request.

Document fitness assessment indicating ability to tolerate conventional or reduced‑intensity conditioning as appropriate.

Note

Follow ASBMT/EBMT and specialty society guidelines for evaluation steps

Refer to ASBMT, EBMT, and specialty society guidelines cited in the policy for comprehensive pretransplant evaluation steps and workup procedures to support authorization and candidate selection.

Transplant Center and Program Requirements

Note

Use specialized transplant programs (see main policy and cross‑references)

Policy history and cross‑references (for example, cord blood policy #285) imply that transplants should be performed by specialized transplant programs; consult the main policy for center accreditation and program expectations.

Note

Consult main policy for accreditation and volume requirements

Refer to the main policy for specific center accreditation (e.g., FACT) and volume requirements; this section does not detail accreditation or minimum procedure volumes.

Note

Multicenter outcomes and EBMT reports are cited

The policy cites large multicenter outcome studies and EBMT reports in the references to inform center‑level outcomes and expectations for transplant programs.

Post-Transplant Coverage and Follow-up

Post-transplant care — HCPCS S2150 global definition and coverage note

HCPCS S2150 descriptionBone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical, surgical, diagnostic and emergency services).

Global definition scopeS2150’s global definition explicitly includes harvesting, transplantation, high-dose chemotherapy, and post-transplant care services (drugs; hospitalization; medical, surgical, diagnostic and emergency services).

Post-transplant days includedPost-transplant care days are included in the S2150 global definition (covers the number of days of post-transplant care as part of the global service).

Coding contextHCPCS S2150 is listed alongside other HCPCS codes used for cord blood and marrow/stem-cell harvesting and transplantation services included in policy coding guidance.

Outcome and survivorship monitoring — long-term outcomes and follow-up study citations

Background and Context

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a treatment option used to cure or substantially alter the course of select hematologic, immunologic, metabolic, and genetic disorders. Indications include hemoglobinopathies, bone marrow failure syndromes, primary immunodeficiencies, certain inherited metabolic diseases, and genetic skeletal disorders; decisions about transplant candidacy are indication‑specific and depend on clinical context and expected benefit.

Definitions

Allogeneic hematopoietic stem cell transplantation (HCT) — definition

DefinitionTransplantation of hematopoietic stem cells from a donor to a recipient to restore bone marrow and immune function (allogeneic HCT).

Stem cell sourcesDonor-derived hematopoietic stem cells may be obtained from bone marrow, peripheral blood, or umbilical cord blood.

HLA compatibility importanceIn allogeneic transplantation, donor–recipient immunologic compatibility is critical and is established by HLA typing (HLA-A, -B, and -DR loci).

Reduced-intensity conditioning (RIC) — definition and description

RIC definitionReduced-intensity conditioning (RIC) refers to pretransplant regimens using lower doses of cytotoxic drugs or less intense radiotherapy than traditional myeloablative conditioning, intended to reduce treatment-related morbidity and nonrelapse mortality while allowing graft-versus-malignancy effects to develop.

References and Evidence

The bibliography accompanying this policy contains the primary references and guideline citations used to support coverage determinations. For requests that require clinical justification, reviewers and providers should consult these indexed references for disorder‑specific outcomes, long‑term follow‑up, and guideline recommendations.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyAllogeneic Hematopoietic Stem Cell Transplantation (allo‑HCT)

Policy CodePolicy 190

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit initial prior authorization requests using Authorization Manager and include the servicing provider's and facility's NPI.

SourceLink

On This Page

supported by chunk 19

Bone marrow failure syndromes: Inherited marrow-failure disorders (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan, Shwachman-Diamond) have high morbidity and risk of progression to MDS/AML; allo-HCT can restore hematopoiesis and is potentially lifesaving.N/A

supported by chunk 21

Primary immunodeficiencies: Severe combined immunodeficiency and other profound primary immunodeficiencies cause early mortality from infections; bone marrow transplantation is the definitive curative treatment.N/A

supported by chunk 23

Inherited metabolic diseases: Many lysosomal and peroxisomal storage disorders are progressive and fatal in childhood; allo-HCT can supply donor-derived enzyme to tissues inaccessible to conventional enzyme replacement for select disorders (eg, Hurler syndrome), though benefit varies by disorder.N/A

supported by chunk 25 and 10

Genetic skeletal disorders: Infantile malignant osteopetrosis is typically fatal in early childhood due to marrow failure and infections; allo-HCT is the only curative therapy.N/A

supported by chunk 28 and 11

Enter the appropriate servicing provider's NPI or provider ID (the operating surgeon or treating clinician), not the billing group.

Enter the facility's NPI or provider ID where the services will be performed.

Documentation Required

Required Clinical Documentation

Required clinical documentation — submit all relevant documentation to support medical necessity and member eligibility. Failure to provide required clinical documentation may result in delayed processing or denial.

Clinical history and indication for hematopoietic cell transplantation (HCT), including prior therapies and response (e.g., for sickle cell: chronic transfusions, hydroxyurea, other interventions).
Documentation of alternative treatment pathway considerations and rationale for proceeding to allogeneic HCT (eg, disease severity, failed/insufficient response to alternatives, curative intent for hemoglobinopathies).
Source of hematopoietic stem cells (autologous, allogeneic — bone marrow, peripheral blood, or umbilical cord blood) and donor relationship/compatibility.
HLA typing results and documentation of donor–recipient matching.
Relevant laboratory and diagnostic test results, disease staging or classification, and prior treatment records.
Procedure-specific plans including conditioning regimen, planned graft source, and intended facility.

Documentation Required

Clinical Rationale and Supporting Literature

Clinical rationale and supporting literature — provide a concise clinical rationale linking the member's condition to the requested procedure and cite pertinent peer-reviewed evidence or guidelines when available. Absence of guideline-based indications or supporting literature increases the risk of denial.

State why HCT is medically necessary for this member (eg, curative intent for thalassemia or sickle cell disease after consideration of alternatives).
Attach relevant peer-reviewed references, guideline excerpts, or expert consensus supporting the indication (for example, ASBMT guidance and cited literature on HCT for hemoglobinopathies).
Include disease-specific references where available (see policy reference list for exemplar studies and reviews).

Note

Treatment Pathway Context

Treatment pathway context — include documentation of prior and alternative therapies considered and attempted before allo-HCT where applicable. This contextual information is required to demonstrate that transplantation is the appropriate next step in the treatment pathway.

For sickle cell disease: document trials of hydroxyurea, chronic transfusion therapy, and other disease-modifying interventions and the clinical reasons these are insufficient or inappropriate.
For thalassemia: document transfusion dependence, iron overload management, and other relevant disease-specific management prior to transplantation.

Denial Risk

Not Applicable Without Guideline-Based Indication / Denial Risk

Provider action note — reference-section applicability and denial risk: If the member’s clinical presentation does not meet guideline-based indications or the required documentation listed above is not provided, the request may be denied. Inclusion of procedure or diagnosis codes in this policy is informational only and does not guarantee coverage or reimbursement.

Failure to meet medical necessity criteria and provide supporting documentation may lead to denial per member contract.
Coding inclusion is informational; always verify coverage under the member’s contract.

Long-term outcomes citedMultiple long-term outcome and follow-up studies are referenced in the bibliography (see cited studies on transplantation outcomes for inherited metabolic disorders, hemoglobinopathies, and osteopetrosis).

Inherited metabolic disorders evidenceReferences include multicenter and long-term series for Hurler, Hunter, Sanfilippo and other lysosomal disorders documenting variable outcomes after HCT (e.g., Aldenhoven et al. for Hurler syndrome; Guffon et al. for Hunter syndrome).

Primary immunodeficiency and osteopetrosis outcomesLarge cohort and EBMT reports are cited for primary immunodeficiencies and autosomal recessive osteopetrosis documenting long-term transplant outcomes (e.g., Chiesa et al.; Driessen et al.).

RIC regimens span from nearly myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to disease and patient condition.

Clinical goalThe goal is to balance relapse risk from residual disease against nonrelapse mortality by reducing immediate toxicity while facilitating donor engraftment and subsequent graft-versus-malignancy effect.

ASBMT indications — guideline definition reference

ASBMT guideline referenceIndications for autologous and allogeneic hematopoietic cell transplantation are defined in the ASBMT guideline: Majhail NS et al., Biol Blood Marrow Transplant. Nov 2015;21(11):1863-1869 (PMID 26256941).

Use in prior authorizationPrior authorization decisions should reference ASBMT indications and the evidence cited in the policy bibliography.

Clinical guidance roleASBMT guidelines serve as a primary society guideline source for establishing transplant indications referenced in this policy.